QL47 B is a biotin-conjugated derivative of the potent BTK inhibitor QL47, exhibiting an IC50 of 1.3 μM. This tool compound enables research into BTK signaling in vitro and has demonstrated anti-tumor efficacy in relevant cellular and in vivo models for oncology studies.